Two Sigma Advisers LP Has $12.67 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Two Sigma Advisers LP decreased its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 17.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 280,500 shares of the company's stock after selling 59,500 shares during the quarter. Two Sigma Advisers LP owned 0.48% of Twist Bioscience worth $12,673,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Signaturefd LLC boosted its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after buying an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience during the second quarter valued at about $43,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience during the second quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after buying an additional 381 shares in the last quarter.

Insider Activity

In other news, insider Dennis Cho sold 3,104 shares of Twist Bioscience stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $134,123.84. Following the completion of the sale, the insider now directly owns 75,289 shares in the company, valued at $3,253,237.69. The trade was a 3.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares of the company's stock, valued at approximately $3,068,728.57. This represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 101,787 shares of company stock worth $4,584,508 in the last three months. 3.92% of the stock is owned by insiders.

Twist Bioscience Trading Down 0.2 %

NASDAQ TWST traded down $0.09 during trading on Tuesday, reaching $51.56. 616,385 shares of the company's stock were exchanged, compared to its average volume of 942,329. Twist Bioscience Co. has a fifty-two week low of $26.51 and a fifty-two week high of $60.90. The firm has a market capitalization of $3.06 billion, a PE ratio of -14.35 and a beta of 1.82. The company's fifty day simple moving average is $44.49 and its 200-day simple moving average is $46.51.

Wall Street Analysts Forecast Growth

TWST has been the subject of several analyst reports. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Scotiabank upped their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a report on Tuesday, November 19th. TD Cowen reaffirmed a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Finally, Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $51.00.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.